Publication at First Faculty of Medicine |
2020
Abstract
Drugs that have altered the long-term prognosis of multiple myeloma patients over the past few years include monoclonal antibodies (daratumumab and elotuzumab), new generation proteasome inhibitors (carfilzomib, ixazomib) and histone deacetylase inhibitors. New procedures, currently used only in clinical studies, are also infusion of genetically modified T-cells expressing synthetic chimeric antigen receptors ( CARs, CAR-T cells) against the myeloma cells surface receptors or use of bispecific antibodies that are capable of inducing an immune response against the tumour.
The last treatment approved for clinical practice in 2019 is selinexor, a selective inhibitor of exportin 1.